Fernando Díaz González-Colmenero

Fernando Díaz González-Colmenero

Auto-generated profile, based on publicly available information

Fernando Díaz González-Colmenero

Department of Psychiatry, Massachusetts General Hospital, Boston, MA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in Journal of Affective Disorders
Verified
Journal Article
Closed access
FGFernando Díaz González-Colmenero
Fernando Díaz González-Colmenero
JMJuan Manuel Millan-Alanis
Juan Manuel Millan-Alanis
FBFrancisco J Barrera
Francisco J Barrera
ESErasmo Saucedo-Uribe
Erasmo Saucedo-Uribe

20 June 2025 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
MSMaría O. Sordia‐Piñeyro
María O. Sordia‐Piñeyro
LSLuis H. Sordia‐Hernández
Luis H. Sordia‐Hernández
FMFelipe A. Morales‐Martínez
Felipe A. Morales‐Martínez
PLPaloma C. Leyva‐Camacho
Paloma C. Leyva‐Camacho
FDFernando Díaz‐Colmenero
Fernando Díaz‐Colmenero
AAAlejandro Aldape‐Arellano
Alejandro Aldape‐Arellano

25 December 2023 in Psychiatry Investigation
Verified
Journal Article
Open access
PDF file
EUErasmo Saucedo Uribe
Erasmo Saucedo Uribe
SMSamuel Enrique Olivares Mundo
Samuel Enrique Olivares Mundo
RGRaul Ricardo Medrano Garza
Raul Ricardo Medrano Garza
FGFernando Diaz Gonzalez-Colmenero
Fernando Diaz Gonzalez-Colmenero
LSLorena Martinez Sanchez
Lorena Martinez Sanchez
SRSandra Sabrina Rojo-Garza
Sandra Sabrina Rojo-Garza
Objective To find the safety of long-acting injectable antipsychotics (LAIs) compared to each other, and/or placebo in the treatment of schizophrenia (SCZ) and/or schizoaffective disorder (SZA).Methods We performed a systematic review and a network meta-analysis of randomized controlled trials (RCTs) comparing the safety of LAIs versus other LAIs or placebo in adults diagnosed with SCZ or SZA. The primary outcomes were treatment emergent adverse events (TEAEs), serious treatment emergent adverse events (STEAEs), and deaths. The secondary outcomes included treatment discontinuations due to adverse events and all-cause discontinuations.Results Seventeen RCTs were included (n=7,908). There were no significant differences between LAIs and placebo in the risk of presenting TEAEs. LAIs had a significant lower risk of presenting STEAEs except for aripiprazole. No significant differences in deaths were found. LAIs showed a significant protective effect against all-cause discontinuation, except for haloperidol. Only aripiprazole had a significantly lower risk of treatment discontinuation due to adverse events.Conclusion We found no significant differences in the risk of presenting TEAEs between LAIs and placebo. The majority of LAIs had a significantly lower risk of presenting STEAEs than placebo. Development of international guidelines for the report of safety outcomes related to antipsychotics especially for LAIs in clinical trials could minimize report and interpretation biases and improve the accuracy of posterior meta-analysis.

1 April 2022 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
FGFernando Díaz González-Colmenero
Fernando Díaz González-Colmenero
MGMariano García-Campa
Mariano García-Campa
RRRene Rodríguez-Gutiérrez
Rene Rodríguez-Gutiérrez

11 June 2026 in Blood Advances
Verified
Journal Article
Open access
PDF file
DSDaniel A. Schaefer
Daniel A. Schaefer
MGMichelle Guo
Michelle Guo
EKEmma P. Keane
Emma P. Keane
MSM. Tim Song
M. Tim Song
ILIsabella S. Larizza
Isabella S. Larizza
HAHermioni L. Amonoo
Hermioni L. Amonoo
There is no comprehensive synthesis of supportive care interventions for patients with hematologic malignancies receiving transplantation and cellular therapies (TCTs). This systematic review and meta-analysis aimed to characterize randomized controlled trials (RCTs) of TCT supportive care interventions and examine effects on patient-reported outcomes (PROs). We systematically searched MEDLINE, Embase, CINAHL, PsycInfo, Web of Science, and Cochrane Central Register of Controlled Trials. Risk of bias was assessed using Cochrane Risk of Bias 2.0. Findings were grouped by intervention and PRO type and synthesized narratively, with exploratory random-effects meta-analyses estimating pooled intervention effects on anxiety, depression, and quality of life (QOL). Fifty-three RCTs (1992-2025) met inclusion criteria. The search yielded only RCTs of hematopoietic stem cell transplantation (HSCT) recipients, although we included all transplantation and cellular therapies. Studies varied in sample size (11-711), participant demographics (mean age, 33-63 years; 22%-64% women), and PROs. There were 9 intervention categories: cognitive behavioral (n = 5), exercise only (n = 17), expressive helping (n = 2), mind-body/stress management (n = 7), multimodal (exercise plus another modality; n = 6), music/art (n = 12), palliative care (n = 2), positive psychology (n = 1), and self-management/self-efficacy (n = 5). Interventions were mostly feasible and acceptable, with promising improvements in psychological distress, QOL, and physical outcomes. Meta-analysis showed nonsignificant trends toward exercise interventions improving QOL (standardized mean differences [SMD], 0.09) and music/art interventions reducing acute depressive symptoms (SMD, −0.26). Among patients undergoing HSCT for hematologic malignancies, supportive care interventions show feasibility, acceptability, and promise for improving PROs. However, larger, rigorously designed RCTs using standardized PRO measures are needed to establish efficacy.